医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

JC Medical TAVI System Implanted First Time Outside China

2016年02月25日 PM09:00
このエントリーをはてなブックマークに追加


 

BURLINGAME, Calif.

JC Medical, Inc. announced today that it has successfully completed an implantation of its J-Valve bioprosthesis using the Ausper transapical delivery device in Vancouver, Canada. The J-Valve Ausper system represents the next generation transcatheter aortic valve implantation (TAVI) system and has been previously used in more than 100 patients in China. This operation is the first implantation of the J-Valve Ausper system outside of China.

The implantation was performed by Jian Ye, M.D., clinical professor of surgery and director of cardiac surgery research, and John Webb, M.D., director of interventional cardiology at St. Paul’s Hospital in Vancouver.

The patient suffered from debilitating heart failure symptoms due to severe aortic regurgitation and was considered to be at a high risk for open-heart aortic valve replacement surgery due to his condition.

“The J-Valve is a unique valve designed for both aortic regurgitation (non-calcified valves) and aortic stenosis (severe calcification),” Ye said. “Most TAVI devices are designed for aortic stenosis. Up to date, there are no transcatheter valves approved for the treatment of pure aortic regurgitation in North America. The J-Valve is relatively easier to implant compared with other valves, and provides true anatomical positioning. Furthermore, no rapid ventricular pacing is required during the entire procedure, which reduces myocardial stress. The clinical trial in China has showed good early outcomes.”

Aortic regurgitation, also known as aortic insufficiency, and aortic stenosis are both potentially life-threatening conditions related to the aortic valve that directs blood out of the heart to the rest of the body. An estimated 12 million people worldwide have heart valve diseases. Currently approved minimally invasive TAVI devices are only indicated for use in patients with aortic stenosis. The J-Valve Ausper TAVI System is designed to treat aortic regurgitation, as well as aortic stenosis.

“We are very pleased that our J-Valve system could help the patient in Canada,” said Ji Zhang, M.D., founder and CEO of JC Medical. “We thank the physician group who has recognized this unique clinical solution.”

JC Medical is currently pursuing market approval of the J-Valve Ausper TAVI System in China.

About JC Medical, Inc.
JC Medical, Inc. is a privately held, venture-backed developer and manufacturer of TAVI systems. The company’s first product is a next generation TAVI system that addresses an unmet need in patients with aortic regurgitation as well as aortic stenosis. The company has operational sites in Burlingame, Calif., and Suzhou, China.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160225005309/en/

CONTACT

Nobles Global Communications
Diana Soltesz, 818-618-5634
diana@noblesgc.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果